Facilities in multiple states assure depth of supply of source material for consistency and quality throughout the supply chain. Patented technology to generate multiple quality grades for divergent applications, teamed with superior onsistency upon which our clients can rely & build brands.

Highly scalable manufacturing process, to ensure inventory for an
increasing demand.
AgraTech International has developed a biotech enterprise focused on chitosan,
a biomaterial processed from crustacean shells (shrimp, crawfish, crab, etc.). AgraTech is testing its own chitosan-based product (patent pending) that
permanently bonds to glass to create a hydrophobic shield. This value added
product will generate licensing fees and royalties from glass and auto
manufacturers, military, building construction and the optics industry.

AgraTech has filed a provisional patent on a sprayable hemostatic agent designed
to treat submucosal bleeding in the nose, the gastrointestinal tract and other
areas. The technology is currently in development.
AgraTech has developed a biotech enterprise focused on chitosan,
a biomaterial processed from crustacean shells (shrimp, crawfish, crab, etc.).

AgraTech will be the only commercial
manufacturer of chitosan in the US.

Demand for chitosan is outpacing supply as new uses are discovered and new chitosan-based products are developed.

While demand is already increasing in existing markets such as nutraceuticals and cosmetics for high quality chitosan, Agratech has been actively researching new markets as well. Agratech holds key patents or patents pending for an incredible array of new applications. We are poised to serve as market leader among chitosan suppliers worldwide.